严重血小板减少症中显性消化道出血内镜干预的结局
回顾性研究纳入144例血小板计数20至<50×10³/mL的显性消化道出血住院患者,在就诊24小时内行内镜。诊断阳性率68%(肝硬化61% vs 非肝硬化79%,P=.04),治疗阳性率60%,初始止血率94%且仅1例不良事件。干预后全队列红细胞和血小板输注中位数下降,1个月和1年再出血率分别为22%和30%,全因死亡率分别为19%和37%。
要点
- 严重血小板减少的显性消化道出血行内镜初始止血率94%,仅1例不良事件。
- 诊断阳性率肝硬化61% vs 非肝硬化79%(P=.04),治疗阳性率两组无差异。
- INR>2为再出血预测因素,1个月和1年再出血率分别为22%和30%。
核心结论
- 在该研究队列中,肝硬化与非肝硬化严重血小板减少患者的显性消化道出血内镜干预看似安全,诊断和治疗阳性率中等,初始止血率高,并与红细胞和血小板输注显著减少相关。
- 再出血率和全因死亡率仍然较高。
研究设计与样本
- 回顾性研究,纳入因显性消化道出血在就诊24小时内行内镜、血小板计数20至<50×10³/mL的住院患者144例。
主要发现
- 中位血小板计数41×10³/mL,61%为肝硬化。
- 诊断阳性率68%(肝硬化61% vs 非肝硬化79%,P=.04);治疗阳性率60%(59% vs 60%,P=1.00)。
- 初始止血率94%,发生1例不良事件。
- 干预后全队列红细胞和血小板输注中位数下降;1个月再出血率22%,1年30%,两组间无差异。
- 1个月全因死亡率19%,1年37%;消化道出血相关死亡率1个月3%,1年4%,肝硬化与非肝硬化间无显著差异。
关键数值与推荐
- INR>2为再出血预测因素。
- 死亡预测因素包括INR>2、活化部分凝血活酶时间>38秒、低血压、入住重症监护病房及肺部合并症。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Gastrointestinal bleeding (GIB) in the setting of thrombocytopenia raises concerns about endoscopic procedure risk. We aimed to assess the safety and outcomes of endoscopy for overt GIB in the setting of severe thrombocytopenia in liver cirrhosis (LC) and non-liver cirrhosis (NLC). METHODS: This is a retrospective study on inpatients who underwent endoscopy within 24 hours of presentation for overt GIB with a platelet count (PC) of 20 to <50 × 103/mL. Outcomes included diagnostic and therapeutic yields, procedural adverse events, packed red blood cell (pRBC) and platelet transfusions, recurrent bleeding rate, and all-cause and GIB-related mortality. RESULTS: One hundred forty-four patients were identified. The median PC was 41 × 103/mL and 61% had LC. The diagnostic yield was 68% (LC = 61%, NLC = 79%, P = .04). Therapeutic yield was 60% (59% vs 60%, P = 1.00). The initial hemostasis rate was 94% with one adverse event. The median number of pRBC and platelet transfusions decreased after intervention in the entire cohort. Recurrent bleeding rates were 22% at 1 month and 30% at 1 year, with no differences between groups. An increased international normalized ratio (INR) >2 was a predictor of recurrent bleeding. All-cause mortality was 19% at 1 month and 37% at 1 year, whereas GIB-associated mortality in our cohort was only 3% at 1 month and 4% at 1 year, with no significant difference between LC and NLC. Predictors of mortality were INR >2, activated partial thromboplastin time >38 seconds, hypotension, intensive care unit admission, and pulmonary comorbidities. CONCLUSION: In this study cohort, we observed that endoscopy for overt GIB in the setting of severe thrombocytopenia in patients with LC and NLC appears safe, has moderate diagnostic and therapeutic yields with high initial hemostasis rate, and is associated with a significant decrease in pRBC and platelet transfusions. Recurrent bleeding and all-cause mortality rates remain high.
引用
- Ramos GP, Binder M, Hampel P, et al. Outcomes of endoscopic intervention for overt GI bleeding in severe thrombocytopenia. Gastrointest Endosc. 2018. PMID: 29408558. doi:10.1016/j.gie.2018.01.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。